LT2977385T - Humanizuoti antikūnai, specifiniai amiloido-beta peptido protofibrilinei formai - Google Patents

Humanizuoti antikūnai, specifiniai amiloido-beta peptido protofibrilinei formai

Info

Publication number: LT2977385T
Authority: LT; Lithuania
Prior art keywords: amyloid; antibodies specific; beta peptide; humanised antibodies; protofibrillar form
Prior art date: 2009-05-12

Application number

LTEP15160538.3T

Other languages

English (en)

Inventor

Nicolas Baurin

Francis Blanche

Béatrice Cameron

Marc Duchesne

Vincent Mikol

Souad Naimi

Laurent Pradier

Yi Shi

Original Assignee

Sanofi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-12

Filing date

2010-05-11

Publication date

2018-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41591699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2977385(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-05-11 Application filed by Sanofi filed Critical Sanofi

2018-04-10 Publication of LT2977385T publication Critical patent/LT2977385T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LTEP15160538.3T 2009-05-12 2010-05-11 Humanizuoti antikūnai, specifiniai amiloido-beta peptido protofibrilinei formai LT2977385T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0953133A FR2945538B1 (fr)	2009-05-12	2009-05-12	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.

Publications (1)

Publication Number	Publication Date
LT2977385T true LT2977385T (lt)	2018-04-10

Family

ID=41591699

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15160538.3T LT2977385T (lt)	2009-05-12	2010-05-11	Humanizuoti antikūnai, specifiniai amiloido-beta peptido protofibrilinei formai

Country Status (41)

Country	Link
US (4)	US8614299B2 (lt)
EP (3)	EP3050898B1 (lt)
JP (2)	JP2012526541A (lt)
KR (1)	KR101783058B1 (lt)
CN (1)	CN102459336B (lt)
AR (1)	AR076670A1 (lt)
AU (1)	AU2010247215B2 (lt)
BR (1)	BRPI1012853B1 (lt)
CA (1)	CA2761665A1 (lt)
CL (1)	CL2011002831A1 (lt)
CO (1)	CO6460745A2 (lt)
CR (1)	CR20110585A (lt)
CY (2)	CY1116842T1 (lt)
DK (2)	DK2977385T3 (lt)
EA (1)	EA028357B1 (lt)
EC (1)	ECSP11011452A (lt)
ES (2)	ES2664409T3 (lt)
FR (1)	FR2945538B1 (lt)
GT (1)	GT201100283A (lt)
HR (3)	HRP20150776T1 (lt)
HU (1)	HUE036737T2 (lt)
IL (1)	IL216237B (lt)
LT (1)	LT2977385T (lt)
MA (1)	MA33350B1 (lt)
MX (1)	MX2011012060A (lt)
MY (1)	MY159398A (lt)
NI (1)	NI201100195A (lt)
NZ (1)	NZ596540A (lt)
PE (1)	PE20120906A1 (lt)
PL (2)	PL2430049T3 (lt)
PT (2)	PT2977385T (lt)
RS (1)	RS54122B1 (lt)
SG (1)	SG176155A1 (lt)
SI (2)	SI2430049T1 (lt)
SV (1)	SV2011004058A (lt)
TN (1)	TN2011000571A1 (lt)
TW (2)	TWI583791B (lt)
UA (1)	UA107574C2 (lt)
UY (1)	UY32633A (lt)
WO (1)	WO2010130946A1 (lt)
ZA (1)	ZA201108301B (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101377535B1 (ko)	2007-11-16	2014-03-27	더 락커펠러 유니버시티	원섬유 형태의 베타아밀로이드 단백질에 대해 특이적인 항체
AR085302A1 (es) *	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
JP2013159596A (ja) *	2012-02-08	2013-08-19	Nihon Univ	β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
EP2968503B1 (en)	2013-03-15	2018-08-15	Intrinsic LifeSciences LLC	Anti-hepcidin antibodies and uses thereof
CA3090240A1 (en)	2014-08-08	2016-02-11	Alector Llc	Anti-trem2 antibodies and methods of use thereof
WO2016049036A1 (en)	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
WO2016164637A1 (en)	2015-04-07	2016-10-13	Alector Llc	Anti-sortilin antibodies and methods of use thereof
CN116063499A (zh)	2015-06-12	2023-05-05	艾利妥	抗cd33抗体及其使用方法
EP3307779A2 (en)	2015-06-12	2018-04-18	Alector LLC	Anti-cd33 antibodies and methods of use thereof
CN107849125A (zh)	2015-07-21	2018-03-27	生命北极神经科学公司	用于治疗靶向聚集的肽的创伤性脑损伤的方法
CN115960235A (zh)	2015-08-28	2023-04-14	艾利妥	抗siglec-7抗体及其使用方法
CN117069841A (zh)	2015-10-06	2023-11-17	艾利妥	抗trem2抗体及其使用方法
EP3368575B1 (en)	2015-10-29	2025-05-07	Alector LLC	Anti-siglec-9 antibodies and methods of use thereof
WO2017152102A2 (en)	2016-03-04	2017-09-08	Alector Llc	Anti-trem1 antibodies and methods of use thereof
JP2020500020A (ja)	2016-11-14	2020-01-09	ノバルティスアーゲー	融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
EP3354278A1 (en)	2017-01-31	2018-08-01	Sanofi	Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
EP3625258A1 (en)	2017-05-16	2020-03-25	Alector LLC	Anti-siglec-5 antibodies and methods of use thereof
WO2019023247A1 (en)	2017-07-25	2019-01-31	Immutics, Inc.	TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
KR102733407B1 (ko)	2017-08-03	2024-11-21	알렉터 엘엘씨	항-cd33 항체 및 이의 이용 방법
BR112019022752A2 (pt)	2017-08-03	2020-05-19	Alector Llc	anticorpos anti-trem2 e métodos de uso dos mesmos
PE20210342A1 (es)	2018-05-25	2021-02-23	Alector Llc	Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3801767A1 (en)	2018-06-08	2021-04-14	Alector LLC	Anti-siglec-7 antibodies and methods of use thereof
MX2019012869A (es)	2018-07-13	2020-01-23	Alector Llc	Anticuerpos anti-sortilina y metodos para su uso.
MX2021000933A (es)	2018-07-27	2021-05-27	Alector Llc	Anticuerpos anti-siglec-5 y métodos para su uso.
US12247073B2 (en)	2018-08-31	2025-03-11	Alector Llc	Anti-CD33 antibodies and methods of use thereof
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
JP2022523333A (ja)	2019-01-30	2022-04-22	トゥルーバインディング，インコーポレイテッド	抗ｇａｌ３抗体およびその使用
TW202110878A (zh)	2019-05-16	2021-03-16	法商賽諾菲公司	在神經系統中表現抗原結合蛋白
CN114245807B (zh)	2019-06-25	2025-05-02	吉利德科学公司	Flt3l-fc融合蛋白和使用方法
WO2021035033A1 (en) *	2019-08-20	2021-02-25	The Curators Of The University Of Missouri	Amyloid-beta antibodies
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
EP4073119A1 (en)	2019-12-12	2022-10-19	Alector LLC	Methods of use of anti-cd33 antibodies
EP4157338A4 (en)	2020-05-26	2024-11-13	TrueBinding, Inc.	METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PH12023500005A1 (en)	2020-08-25	2023-08-14	Gilead Sciences Inc	Multi-specific antigen binding molecules targeting hiv and methods of use
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
WO2023081898A1 (en)	2021-11-08	2023-05-11	Alector Llc	Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
US6136310A (en)	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP2082749A3 (en)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prevention and treatment of Alzheimer's disease
JP2005500806A (ja) *	2000-09-15	2005-01-13	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
TWI255272B (en) *	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
WO2005087177A2 (en) *	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
SE0401601D0 (sv) *	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
CN102702353A (zh) *	2004-07-09	2012-10-03	中外制药株式会社	抗-磷脂酰肌醇蛋白聚糖3抗体
MX2007000998A (es) *	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
AU2005291486A1 (en) *	2004-10-01	2006-04-13	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Novel antibodies directed to the mammalian EAG1 ion channel protein
CA2589860A1 (en) *	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
JP2009533653A (ja) *	2006-03-22	2009-09-17	ギロスパテントアーべー	プレックス（ｐｌｅｘ）方法
ATE492561T1 (de) *	2006-03-23	2011-01-15	Bioartic Neuroscience Ab	Verbesserte protofibrilselektive antikörper und deren verwendung
DK2099826T3 (da) *	2007-01-05	2014-01-20	Univ Zuerich	Anti-beta-amyloid-antistof og anvendelser deraf
NZ597466A (en) *	2007-03-01	2013-08-30	Symphogen As	Recombinant anti-epidermal growth factor receptor antibody compositions
NO2195023T3 (lt)	2007-08-29	2018-08-04
KR101377535B1 (ko) *	2007-11-16	2014-03-27	더 락커펠러 유니버시티	원섬유 형태의 베타아밀로이드 단백질에 대해 특이적인 항체
SI3211005T1 (sl) *	2008-07-08	2021-06-30	Geneuro Sa	Terapevtska uporaba specifičnega liganda pri boleznih, povezanih z MSRV
CA2754764A1 (en) *	2009-03-10	2010-09-16	Baylor Research Institute	Antigen presenting cell targeted cancer vaccines
CN105884903B (zh) *	2009-03-10	2019-12-06	贝勒研究院	靶向抗原呈递细胞的疫苗
TWI508976B (zh) *	2009-04-21	2015-11-21	Univ Rockefeller	對β－類澱粉蛋白之基原纖維形式具專一性之抗體

2009
- 2009-05-12 FR FR0953133A patent/FR2945538B1/fr not_active Expired - Fee Related
2010
- 2010-05-11 EP EP16155574.3A patent/EP3050898B1/fr not_active Not-in-force
- 2010-05-11 SI SI201030968T patent/SI2430049T1/sl unknown
- 2010-05-11 SG SG2011085255A patent/SG176155A1/en unknown
- 2010-05-11 UA UAA201114656A patent/UA107574C2/ru unknown
- 2010-05-11 TW TW105112498A patent/TWI583791B/zh not_active IP Right Cessation
- 2010-05-11 ES ES15160538.3T patent/ES2664409T3/es active Active
- 2010-05-11 MY MYPI2011005458A patent/MY159398A/en unknown
- 2010-05-11 AU AU2010247215A patent/AU2010247215B2/en not_active Ceased
- 2010-05-11 CA CA2761665A patent/CA2761665A1/fr not_active Abandoned
- 2010-05-11 HR HRP20150776TT patent/HRP20150776T1/hr unknown
- 2010-05-11 RS RS20150459A patent/RS54122B1/sr unknown
- 2010-05-11 NZ NZ596540A patent/NZ596540A/xx not_active IP Right Cessation
- 2010-05-11 MX MX2011012060A patent/MX2011012060A/es active IP Right Grant
- 2010-05-11 TW TW099115013A patent/TWI542360B/zh not_active IP Right Cessation
- 2010-05-11 PE PE2011001949A patent/PE20120906A1/es active IP Right Grant
- 2010-05-11 SI SI201031662T patent/SI2977385T1/en unknown
- 2010-05-11 DK DK15160538.3T patent/DK2977385T3/en active
- 2010-05-11 EP EP10728743.5A patent/EP2430049B1/fr active Active
- 2010-05-11 PT PT151605383T patent/PT2977385T/pt unknown
- 2010-05-11 DK DK10728743.5T patent/DK2430049T3/en active
- 2010-05-11 EA EA201171388A patent/EA028357B1/ru not_active IP Right Cessation
- 2010-05-11 HU HUE15160538A patent/HUE036737T2/hu unknown
- 2010-05-11 KR KR1020117029577A patent/KR101783058B1/ko not_active Expired - Fee Related
- 2010-05-11 WO PCT/FR2010/050915 patent/WO2010130946A1/fr not_active Ceased
- 2010-05-11 PL PL10728743T patent/PL2430049T3/pl unknown
- 2010-05-11 ES ES10728743.5T patent/ES2542757T3/es active Active
- 2010-05-11 BR BRPI1012853-0A patent/BRPI1012853B1/pt not_active IP Right Cessation
- 2010-05-11 MA MA34434A patent/MA33350B1/fr unknown
- 2010-05-11 JP JP2012510343A patent/JP2012526541A/ja active Pending
- 2010-05-11 CN CN201080030434.6A patent/CN102459336B/zh not_active Expired - Fee Related
- 2010-05-11 PL PL15160538T patent/PL2977385T3/pl unknown
- 2010-05-11 PT PT107287435T patent/PT2430049E/pt unknown
- 2010-05-11 AR ARP100101602A patent/AR076670A1/es active IP Right Grant
- 2010-05-11 EP EP15160538.3A patent/EP2977385B1/fr not_active Not-in-force
- 2010-05-11 LT LTEP15160538.3T patent/LT2977385T/lt unknown
- 2010-05-11 US US13/319,710 patent/US8614299B2/en not_active Expired - Fee Related
- 2010-05-12 UY UY0001032633A patent/UY32633A/es active IP Right Grant
2011
- 2011-11-08 CR CR20110585A patent/CR20110585A/es unknown
- 2011-11-08 GT GT201100283A patent/GT201100283A/es unknown
- 2011-11-09 IL IL216237A patent/IL216237B/en active IP Right Grant
- 2011-11-10 TN TNP2011000571A patent/TN2011000571A1/fr unknown
- 2011-11-11 NI NI201100195A patent/NI201100195A/es unknown
- 2011-11-11 CO CO11153627A patent/CO6460745A2/es active IP Right Grant
- 2011-11-11 ZA ZA2011/08301A patent/ZA201108301B/en unknown
- 2011-11-11 SV SV2011004058A patent/SV2011004058A/es active IP Right Grant
- 2011-11-11 CL CL2011002831A patent/CL2011002831A1/es unknown
- 2011-11-11 EC EC2011011452A patent/ECSP11011452A/es unknown
2013
- 2013-10-01 US US14/042,942 patent/US9382312B2/en not_active Expired - Fee Related
2015
- 2015-07-14 CY CY20151100622T patent/CY1116842T1/el unknown
- 2015-10-01 JP JP2015195617A patent/JP6310895B2/ja not_active Expired - Fee Related
2016
- 2016-06-02 US US15/171,708 patent/US10112991B2/en not_active Expired - Fee Related
2018
- 2018-03-27 HR HRP20180516TT patent/HRP20180516T1/hr unknown
- 2018-03-27 CY CY20181100343T patent/CY1120413T1/el unknown
- 2018-09-26 US US16/142,666 patent/US20190119365A1/en not_active Abandoned
- 2018-11-27 HR HRP20181985TT patent/HRP20181985T1/hr unknown

Also Published As

Publication number	Publication date
KR20120096950A (ko)	2012-08-31
TWI542360B (zh)	2016-07-21
NI201100195A (es)	2012-02-01
GT201100283A (es)	2013-11-07
HK1167152A1 (en)	2012-11-23
EP2977385A1 (fr)	2016-01-27
UA107574C2 (ru)	2015-01-26
MY159398A (en)	2016-12-30
CY1120413T1 (el)	2019-07-10
MX2011012060A (es)	2012-04-30
HRP20180516T1 (hr)	2018-05-04
SI2430049T1 (sl)	2015-08-31
EP2977385B1 (fr)	2017-12-27
AU2010247215B2 (en)	2015-08-20
PE20120906A1 (es)	2012-08-08
ECSP11011452A (es)	2011-12-30
CY1116842T1 (el)	2017-03-15
EP3050898A1 (fr)	2016-08-03
TWI583791B (zh)	2017-05-21
JP2016028591A (ja)	2016-03-03
BRPI1012853B1 (pt)	2021-08-24
SV2011004058A (es)	2012-06-06
PT2430049E (pt)	2015-09-01
CA2761665A1 (fr)	2010-11-18
UY32633A (es)	2010-12-31
MA33350B1 (fr)	2012-06-01
EP3050898B1 (fr)	2018-08-15
EP2430049A1 (fr)	2012-03-21
KR101783058B1 (ko)	2017-09-28
TW201641690A (zh)	2016-12-01
CN102459336A (zh)	2012-05-16
SG176155A1 (en)	2011-12-29
US10112991B2 (en)	2018-10-30
EP2430049B1 (fr)	2015-04-15
US20160368977A1 (en)	2016-12-22
EA028357B1 (ru)	2017-11-30
RS54122B1 (sr)	2015-12-31
TN2011000571A1 (fr)	2013-05-24
DK2430049T3 (en)	2015-07-20
ZA201108301B (en)	2013-01-30
CL2011002831A1 (es)	2012-05-11
PT2977385T (pt)	2018-04-03
WO2010130946A1 (fr)	2010-11-18
HRP20181985T1 (hr)	2019-01-25
PL2977385T3 (pl)	2018-06-29
BRPI1012853A2 (pt)	2018-06-19
FR2945538A1 (fr)	2010-11-19
HUE036737T2 (hu)	2018-07-30
ES2542757T3 (es)	2015-08-11
CO6460745A2 (es)	2012-06-15
DK2977385T3 (en)	2018-04-16
AR076670A1 (es)	2011-06-29
US20190119365A1 (en)	2019-04-25
US20140105890A1 (en)	2014-04-17
IL216237A0 (en)	2012-01-31
IL216237B (en)	2018-05-31
EA201171388A1 (ru)	2012-05-30
US8614299B2 (en)	2013-12-24
CR20110585A (es)	2011-12-07
AU2010247215A1 (en)	2011-12-15
US20120177639A1 (en)	2012-07-12
CN102459336B (zh)	2016-04-20
FR2945538B1 (fr)	2014-12-26
PL2430049T3 (pl)	2015-09-30
US9382312B2 (en)	2016-07-05
JP2012526541A (ja)	2012-11-01
SI2977385T1 (en)	2018-05-31
JP6310895B2 (ja)	2018-04-11
NZ596540A (en)	2013-05-31
TW201100102A (en)	2011-01-01
HRP20150776T1 (hr)	2015-08-28
ES2664409T3 (es)	2018-04-19

Publication	Publication Date	Title
HUE036737T2 (hu)	2018-07-30	Béta amyloid peptid protofibrilláris formájára specifikus humanizált ellenanyagok
IL217087A0 (en)	2012-02-29	Bispecific antibodies that bind to complement proteins
ZA201208906B (en)	2014-05-28	Humanised antigen binding proteins to myostatin6
ZA201202642B (en)	2013-06-26	Monoclonal antibodies to progastrin and their uses
ZA201107130B (en)	2012-12-27	Preparation of isolated agonist anti-edar monoclonal antibodies
ZA201108536B (en)	2012-09-26	Bispecific antigen binding proteins
IL216002A (en)	2016-07-31	An isolated antibody or antigen-binding fragment from it that binds specifically to 100cd
ZA201202227B (en)	2014-11-26	Monoclonal antibodies
ZA201107511B (en)	2013-06-26	Antibodies specific to cadherin-17
IL217919A0 (en)	2012-03-29	Humanized anti-cdcp1 antibodies
IL221266A (en)	2016-12-29	Process for Recombinant Antibody
EP2542262A4 (en)	2014-02-26	MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20
IL212078A0 (en)	2011-06-30	Antibodies to modified human igf-1/e peptides
EP2484694A4 (en)	2013-05-01	MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
HK1169131A (en)	2013-01-18	Bispecific antibodies that bind to complement proteins
EP2540742A4 (en)	2014-02-12	MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF